Key result
Low BDNF and high vWF predict 12-month adverse cardiovascular events in stable CAD.
Why the study?
Do plasma BDNF and vWF levels predict adverse cardiovascular events at 12 months in patients with stable coronary artery disease?
Cohort (n=234)
Do plasma BDNF and vWF levels predict adverse cardiovascular events at 12 months in patients with stable coronary artery disease?
Effect estimate: AUC 0.804 for inverse BDNF; AUC 0.774 for vWF
Low plasma BDNF and high vWF levels are associated with endothelial dysfunction and can predict adverse cardiovascular events at 1 year in patients with stable coronary artery disease.
May enhance risk stratification in stable CAD; hypothesis-generating and requires prospective validation before clinical adoption.
BACKGROUND: Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in angiogenesis and maintenance of endothelial integrity. Whether circulating BDNF levels are associated with von Willebrand factor (vWF) levels, which are indicators of endothelial dysfunction is not known. This study investigated the association between plasma BNDF and vWF levels and whether these biomarkers could predict cardiovascular events at a 12-month follow-up in patients with stable coronary artery disease (CAD). METHODS: We recruited 234 patients with suspected angina pectoris. Subjects were divided into CAD (n = 143) and control (n = 91) groups based on coronary angiography. Plasma BDNF and vWF levels were measured using ELISA. Patients were followed-up for one year, and information on adverse cardiac events was collected. RESULTS: CAD patients exhibited significantly lower plasma BDNF and higher vWF levels than those of control patients. High vWF levels were associated with low BDNF levels even after adjustment for age, gender, low-density lipoprotein (LDL) levels, and the presence of diabetes mellitus. A receiver operating characteristic curve was used to determine whether low BDNF and high vWF levels could predict adverse cardiovascular events. The area under the curve for vWF and the inverse of BDNF were 0.774 and 0.804, respectively. CONCLUSIONS: These findings suggest that endothelial dysfunction is an important determinant of the impaired circulating BDNF levels, and they further reflected cardiovascular prognosis in stable CAD patients.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2018) conducted a cohort in Stable coronary artery disease (n=234). Plasma BDNF and vWF levels vs. Control patients without CAD was evaluated on Adverse cardiovascular events (AUC 0.804 for inverse BDNF; AUC 0.774 for vWF). Low plasma BDNF and high vWF levels predicted adverse cardiovascular events at 12 months in patients with stable CAD (AUC 0.804 for inverse BDNF and 0.774 for vWF).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: